Santen Pharmaceutical Co Stock EBITDA
SNPHF Stock | USD 9.26 0.00 0.00% |
Santen Pharmaceutical Co fundamentals help investors to digest information that contributes to Santen Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Santen Pink Sheet. The fundamental analysis module provides a way to measure Santen Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Santen Pharmaceutical pink sheet.
Santen |
Santen Pharmaceutical Co Company EBITDA Analysis
Santen Pharmaceutical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Santen Pharmaceutical EBITDA | 53.91 B |
Most of Santen Pharmaceutical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santen Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
According to the company disclosure, Santen Pharmaceutical Co reported earnings before interest,tax, depreciation and amortization of 53.91 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The ebitda for all United States stocks is significantly lower than that of the firm.
Santen EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santen Pharmaceutical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santen Pharmaceutical could also be used in its relative valuation, which is a method of valuing Santen Pharmaceutical by comparing valuation metrics of similar companies.Santen Pharmaceutical is currently under evaluation in ebitda category among related companies.
Santen Fundamentals
Return On Equity | -0.0264 | |||
Return On Asset | -0.001 | |||
Profit Margin | (0.03) % | |||
Operating Margin | (0) % | |||
Current Valuation | 2.6 B | |||
Shares Outstanding | 388.22 M | |||
Shares Owned By Insiders | 3.21 % | |||
Shares Owned By Institutions | 53.50 % | |||
Price To Earning | 14.54 X | |||
Price To Book | 1.39 X | |||
Price To Sales | 0.01 X | |||
Revenue | 266.26 B | |||
Gross Profit | 156.59 B | |||
EBITDA | 53.91 B | |||
Net Income | 27.22 B | |||
Cash And Equivalents | 69.53 B | |||
Cash Per Share | 176.84 X | |||
Total Debt | 32.93 B | |||
Debt To Equity | 0.1 % | |||
Current Ratio | 2.48 X | |||
Book Value Per Share | 780.63 X | |||
Cash Flow From Operations | 46.04 B | |||
Earnings Per Share | 0.50 X | |||
Price To Earnings To Growth | 20,399 X | |||
Number Of Employees | 4.32 K | |||
Beta | 0.38 | |||
Market Capitalization | 2.95 B | |||
Total Asset | 459.98 B | |||
Retained Earnings | 230.22 B | |||
Working Capital | 106.3 B | |||
Current Asset | 156.63 B | |||
Current Liabilities | 50.32 B | |||
Annual Yield | 0.03 % | |||
Five Year Return | 1.57 % | |||
Net Asset | 459.98 B | |||
Last Dividend Paid | 16.0 |
About Santen Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santen Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santen Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santen Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |